logo
Share SHARE
FONT-SIZE Plus   Neg

Cytokinetics Inc. (CYTK) Sank To Over A 2-Month Low On Study Results

Cytokinetics Inc. (CYTK) and Amgen (AMGN) announced Tuesday that data from the ATOMIC-AHF Phase 2 study did not meet its primary endpoint of dyspnea response as measured by the 7-point Likert scale through 48 hours.

Cytokinetics gapped open sharply lower Tuesday and declined during the first hour of trade, before settling into a range. The stock finished with a loss of 2.82 at $7.65 on the highest volume of the year. Cytokinetics dropped to a 2 1/2 month low and fell below its 200-day moving average.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT